CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics

Trial Details

NCT ID
NCT05260528
Phase
PHASE2
Sponsor
Centre Hospitalier Universitaire de Nice
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Cytarabine and Idarubicin
  • CPX-315
Locations (sample)
  • Amiens, France|49.9,2.3
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Besançon, France|47.24878,6.01815
  • Béziers, France|43.34122,3.21402

Key Eligibility Criteria

  • De novo AML
  • No MRC-defining cytogenetic lesion
  • No t(15;17), t(8;21), inv(16) or t(16;16)
  • No NPM1 gene mutation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →